SCHEMBL24852065

SCHEMBL24852065

CC1(Nc2ccc(Cc3cc4ccccc4[nH]c3=O)cc2)CNC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ IL4I1 Q96RQ9 6/20 0.54
▸ KDM4E B2RXH2 7/20 0.46
▸ ALDH1A1 P00352 7/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ HPGD P15428 1/20 0.45
▸ HSD17B10 Q99714 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TSHR P16473 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ IDH1 O75874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24852649 0.82 IL4I1 (0.63) IL4I1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24852647 0.78 IL4I1 (0.63) IL4I1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24851988 0.74 IL4I1 (0.56) IL4I1KDM4EALDH1A1GAAMAPT
SCHEMBL24851784 0.73 IL4I1 (0.60) IL4I1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL32681268 0.73 KDM4E (0.67) IL4I1KDM4EALDH1A1GAAMAPT
SCHEMBL24851822 0.73 IL4I1 (0.56) IL4I1KDM4EALDH1A1GAAMAPT
SCHEMBL30162720 0.73 IL4I1 (0.62) IL4I1KDM4EALDH1A1GAAMAPT
SCHEMBL24852066 0.72 IL4I1 (0.56) IL4I1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24851945 0.72 IL4I1 (0.56) IL4I1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24853036 0.72 IL4I1 (0.55) IL4I1KDM4EALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287022-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-08-29 — — US disclosed
EP-4362978-A1 IL4I1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2024-05-08 — — EP disclosed
WO-2023278222-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2023-01-05 — — WO disclosed
WO-2023278222-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2023-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287022-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL1RN IL4I1 1/4885KDM4E 878/4885ALDH1A1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback